Michael J Kozal, MD

Professor of Medicine (AIDS); Chief Section of Infectious Diseases VA CT Healthcare System ; Director Yale HIV Clinical Trials; Acting Chief, Medical Service VACHS & Vice Chair, VA Medical Service for the Yale Dept. of Internal Medicine

Clinical Interests

  • HIV
  • Sexually Transmitted Diseases

Patient Care

Accepts new patients? No
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Internal Medicine: Infectious Diseases: AIDS Care Program | Viral Hepatitis Program

Yale Medical Group

Board Certifications

  • Infectious Disease AB of Internal Medicine (1994)

  • Internal Medicine AB of Internal Medicine (1991)

Clinical Trials

Conditions Study Title
A Phase 3, Open Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV 1 Positive Subjects (GS-US-292-0109 Amendment 1 dated 19 February 2013)
Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically-Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Edit this profile

Contact Info

Michael J Kozal, MD
Patient Care Locations
Yale Infectious Disease135 College Street, Ste Suite 323
New Haven, CT 06510
VA Connecticut Healthcare
950 Campbell Avenue

West Haven, CT 06516
Mailing Address
Yale AIDS Program135 College Street
New Haven, CT 06510